On June 25, 2026, Kymera Therapeutics announced the completion of enrollment for the global BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis. Enrollment finished ahead of schedule, accelerating the expected topline data readout to year-end 2026, approximately six months earlier than the previous mid-2027 estimate. The company expects to initiate Phase 3 trials by mid-2027, pending regulatory discussions. Kymera Therapeutics is a biopharmaceutical company that develops targeted protein degradation therapies.
